Top PDF Package Leaflet: Information for the user

Package Leaflet: Information for the user

Package Leaflet: Information for the user

Boostrix-IPV is a vaccine used as a booster dose in children from 4 years onwards, teenagers and adults to prevent four diseases: diphtheria, tetanus (lockjaw), pertussis (whooping coug[r]

7 Read more

Do Patients Use a Headline Section in a Leaflet to Find Key Information About Their Medicines? Findings From a User-Test Study

Do Patients Use a Headline Section in a Leaflet to Find Key Information About Their Medicines? Findings From a User-Test Study

The user-testing study did not have a control group. It is possible that a controlled trial with a larger sample might come to different conclusions about the inclusion of a headline section in a PIL. It is possible that the inclusion of headline section has no discernible impact on the reader’s ability to find and understand information in a leaflet. However, there is no evidence that it hinders the reader either, and the findings from the qualitative study suggest it is a popular and welcome inclusion in a PIL. It is important to note that the use of user-testing reflects the methods used currently to test PILs prior to licencing in the EU.
Show more

22 Read more

Do patients use a headline section in a patient information leaflet to find key information about their medicines? Findings from a user-testing study

Do patients use a headline section in a patient information leaflet to find key information about their medicines? Findings from a user-testing study

over a third of the time - in total for 55/140 opportunities (39%). Other notable findings included that 18/20 (90%) of participants used the headline section to find information about what the drug is used for when they initially began the user-test which suggests it was the first place a participant looked in the leaflet when initially trying to find important information. The results also suggest that there was a tendency for patients to use a headline section to locate self-contained pieces of information which might not be naturally positioned elsewhere within the leaflet.
Show more

22 Read more

Package leaflet: Information for the user

Package leaflet: Information for the user

If, for some reason, you are not able to inject Extavia immediately, you can refrigerate the reconstituted solution for up to 3 hours before using it. Do not freeze the solution, and do[r]

22 Read more

(NL/H/ / ) FLECAINIDE ACETATE 100 MG; 50 MG TABLET Package leaflet: Information for the user

(NL/H/ / ) FLECAINIDE ACETATE 100 MG; 50 MG TABLET Package leaflet: Information for the user

Do not use this medicine after the expiry date which is stated on the package after “Do not use after” or “Exp”. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6 Read more

Package leaflet: Information for the user. AVONEX 30 micrograms/0.5 ml solution for Injection (Interferon beta-1a) Pre-filled syringe

Package leaflet: Information for the user. AVONEX 30 micrograms/0.5 ml solution for Injection (Interferon beta-1a) Pre-filled syringe

Your doctor may provide you with an Avostartclip titration kit which enables you to gradually increase your dose at the start of treatment to help limit flu-like symptoms. As you keep [r]

12 Read more

Package leaflet: Information for the user. Betaferon 250 microgram/ml, powder and solvent for solution for injection interferon beta-1b

Package leaflet: Information for the user. Betaferon 250 microgram/ml, powder and solvent for solution for injection interferon beta-1b

► Injection site reactions. Symptoms can be redness, swelling, discolouration, inflammation, pain, hypersensitivity, tissue damage (necrosis). See ‘Warnings and precautions’ in section 2 for more information and what to do, if you experience an injection site reaction. These may be reduced by the use of an auto-injector device. Talk to your doctor, pharmacist or nurse for further information.

23 Read more

Package leaflet: Information for the user. Lyrica 225 mg hard capsules, Lyrica 150 mg hard capsules,

Package leaflet: Information for the user. Lyrica 225 mg hard capsules, Lyrica 150 mg hard capsules,

Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have [r]

8 Read more

Package leaflet: Information for the user. Zercepac 150 mg powder for concentrate for solution for infusion trastuzumab

Package leaflet: Information for the user. Zercepac 150 mg powder for concentrate for solution for infusion trastuzumab

Therefore you should tell your doctor, pharmacist or nurse that you have had Zercepac if you start any new medicine in the 7 months after stopping treatment.. Pregnancy.[r]

9 Read more

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xarelto 10 mg film-coated tablets Rivaroxaban

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xarelto 10 mg film-coated tablets Rivaroxaban

If you become pregnant while you are taking Xarelto, immediately tell your doctor, who will decide how you should be treated.. Driving and using machines.[r]

6 Read more

Package leaflet: Information for the patient. Tramadol hydrochloride/paracetamol 37.5 mg/325 mg Film-coated Tablets

Package leaflet: Information for the patient. Tramadol hydrochloride/paracetamol 37.5 mg/325 mg Film-coated Tablets

Tramadol hydrochloride/Paracetamol is used for the treatment of moderate to severe pain when your doctor decides that a combination of tramadol and paracetamol is necessary.. Tramadol h[r]

7 Read more

Stratagy User Guide is included with this package for your information. Please take the time

Stratagy User Guide is included with this package for your information. Please take the time

New and Saved message queues – The user logs on, presses 1 to play messages and hears first new message (pending LIFO/FIFO option). If there are no new messages, the user is presented to the saved message queue. After listening to all new (saved) messages, the user receives an end of queue prompt. The user is then prompted to press 1 to listen to the next message. If 1 is pressed, the user is returned to the first message in the queue. The user can press 77 to toggle between the new and saved message queues.

6 Read more

Package leaflet: Information for the patient. Pantoprazole Teva Pharma 40 mg gastro-resistant tablets. pantoprazole

Package leaflet: Information for the patient. Pantoprazole Teva Pharma 40 mg gastro-resistant tablets. pantoprazole

metronidazole (or tinidazole), each to be taken two times a day with your pantoprazole tablet. Take the first pantoprazole tablet 1 hour before breakfast and the second pantoprazole tablet 1 hour before your evening meal. Follow your doctor’s instructions and make sure you read the package leaflets for these antibiotics. The usual treatment period is one to two weeks.

7 Read more

Package leaflet: Information for the patient. Fintepla 2.2 mg/ml oral solution fenfluramine

Package leaflet: Information for the patient. Fintepla 2.2 mg/ml oral solution fenfluramine

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

8 Read more

Nocebo effects of a simplified package leaflet compared to unstandardised oral information and a standard package leaflet: a pilot randomised controlled trial

Nocebo effects of a simplified package leaflet compared to unstandardised oral information and a standard package leaflet: a pilot randomised controlled trial

Owing to the nature of the intervention, it was not possible to blind participants and personnel that handed out the PILs. However, although the partici- pants were informed that they participated in an intervention study on health information, they were not aware of the exact purpose of the study. The questionnaires used for assessing outcomes in partici- pants who were allocated to one of the PIL groups included more questions (design of the PIL, know- ledge of AEs, and anxiety while reading the PIL) than the questionnaire used in patients who received no PIL. Therefore, the study personnel who assessed out- comes knew whether the participants received a PIL but were blinded to the type of PIL.
Show more

10 Read more

Package leaflet: Information for the patient

Package leaflet: Information for the patient

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

9 Read more

Package leaflet: Information for the patient. Desloratadine Actavis 5 mg orodispersible tablets desloratadine

Package leaflet: Information for the patient. Desloratadine Actavis 5 mg orodispersible tablets desloratadine

Talk to your doctor, pharmacist or nurse before taking Desloratadine Actavis: - if you have poor kidney function.. Use in children and adolescents.[r]

5 Read more

Travel Sequence Recommendation by Mining User Social Interest and Travelogs Data

Travel Sequence Recommendation by Mining User Social Interest and Travelogs Data

4. System presents is content information on LBSNs with respect to POI properties, user interests, and sentiment indications. Model the three types of information under a unified POI recommendation framework with the consideration of their relationship to check- in actions. The advantage is, user behavior, and demonstrates its power to improve POI recommendation performance on LBSNs. And the disadvantage is contain only small dataset[4].

5 Read more

Package Administration and User Guide

Package Administration and User Guide

The CPU displays are showing CPU usage for a short interval (default 1 second, but this is a configurable value on the PimpMonitor). To see the percentage of CPU used by the System and by the VAS since reboot/service start, place the mouse over the server name just above the graph for this information to be displayed in a tooltip. The MEMORY displays indicate a percentage of RAM. The IO graphs show write (not read) activity. The USERS graph shows current rtsp/s connections. The USERAPPS graph shows rtp connections, which indicates the number of SFT packages opened by different client computers (not necessarily users).
Show more

34 Read more

Show all 10000 documents...

Related subjects